NCT06905327View on ClinicalTrials.gov

A Study to Evaluate the Safety of QCZ484 in Healthy and Mild Hypertensive Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

March 8, 2023

Primary Completion Date

September 25, 2024

Study Completion Date

July 1, 2025

Conditions
Mild Hypertension
Interventions
DRUG

QCZ484

doses of 50, 150, 300 or 600 mg via subcutaneous injection

DRUG

Placebo

via subcutaneous injection

Trial Locations (4)

4006

Novartis Investigative Site, Herston

4506

Novartis Investigative Site, Morayfield

5000

Novartis Investigative Site, Adelaide

0622

Novartis Investigative Site, Auckland

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY